secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001213900-24-022396
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma FY2023 revenue falls 84% to $152K; net loss narrows to $10.9M
----------------------------------------------------------------------------

- Revenue of $152,430 in FY2023, down from $969,783 in FY2022; net loss improved 31% to $10.9M.
- Operating expenses cut to $8.07M from $15.8M; cash and cash equivalents only $60K as of Dec 31, 2023.
- Entered global licensing agreement with AIBL for CNS drugs; received 23M AIBL shares valued at $10 per share.
- Regained Nasdaq compliance for $1.00 bid price and $2.5M stockholders' equity requirements in Aug/Sep 2023.
- Stockholders' equity of $8.39M at year-end; raised $1.75M via registered direct offering in July 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024022396/0001213900-24-022396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024022396/ea0201766-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-022396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer